Ownership and insider activity for Novocure Ltd (NVCR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Price
| Price | $14.94 |
| Market Cap | $1.7B |
| Exchange | NASDAQ |
| Country | CH |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-30 | Puri Michal Nath | A-Award | 1,905 | $21K |
| 2026-06-30 | Leonard Frank X | A-Award | 1,905 | $21K |
| 2026-06-30 | Ben Arye Barak | A-Award | 1,299 | $14K |
| 2026-06-30 | Danziger Asaf | A-Award | 268 | $3K |
| 2026-06-04 | Leonard Frank X | S-Sale | 34,273 | $615K |
| 2026-06-03 | LEUNG GABRIEL | A-Award | 11,610 | |
| 2026-06-03 | LEUNG GABRIEL | A-Award | 16,999 | $275K |
| 2026-06-03 | Stafford Kristin | A-Award | 11,610 | |
| 2026-06-03 | Stafford Kristin | A-Award | 16,999 | $275K |
| 2026-06-03 | Ocean Allyson J | A-Award | 11,610 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $99.8M | $78.6M | $140.6M | $179.4M | $246.2M | $209.6M | $115.3M | $240.8M | $163.8M | $103.4M |
| Short-term Investments | $119.9M | $104.7M | $105.3M | $148.8M | $607.9M | $728.9M | $854.1M | $669.8M | $796.1M | $354.1M |
| Receivables | $6.3M | $29.6M | $36.5M | $64.0M | $100.5M | $97.4M | $106.0M | $77.1M | $102.1M | $115.3M |
| Inventory | $25.5M | $22.0M | $22.6M | $23.7M | $27.4M | $24.4M | $29.4M | $38.2M | $35.1M | $41.1M |
| Total Current Assets | $261.9M | $245.1M | $321.4M | $439.9M | $999.4M | $1.07B | $1.11B | $1.03B | $1.11B | $646.7M |
| Property, Plant & Equipment | $18.6M | $18.1M | $15.4M | $34.6M | $41.6M | $53.9M | $69.0M | $97.7M | $119.6M | $147.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $282.1M | $265.3M | $339.8M | $479.4M | $1.05B | $1.14B | $1.19B | $1.15B | $1.24B | $804.3M |
| Accounts Payable | $18.4M | $17.2M | $26.7M | $36.9M | $53.6M | $72.6M | $85.2M | $94.4M | $105.1M | $122.2M |
| Short-term Debt | 0 | 0 | 0 | $4.6M | $6.5M | $6.7M | 0 | 0 | $558.2M | $11.7M |
| Total Current Liabilities | $36.9M | $50.2M | $64.6M | $86.3M | $113.6M | $142.6M | $158.8M | $179.1M | $756.4M | $223.2M |
| Long-term Debt | $96.2M | $97.3M | $149.3M | $149.4M | $429.9M | $562.2M | $565.5M | $568.8M | $97.3M | $236.7M |
| Total Liabilities | $139.7M | $151.7M | $227.5M | $261.7M | $575.5M | $729.0M | $750.5M | $783.6M | $880.6M | $463.9M |
| Retained Earnings | -$519.9M | -$582.3M | -$643.7M | -$650.9M | -$631.1M | -$685.9M | -$778.5M | -$985.5M | -$1.15B | -$1.29B |
| Total Equity | $142.3M | $113.6M | $112.3M | $217.8M | $476.5M | $410.5M | $441.2M | $362.5M | $360.2M | $340.5M |
| Total Debt | $96.2M | $97.3M | $149.3M | $168.2M | $450.7M | $581.9M | $584.3M | $596.2M | $683.4M | $290.0M |
| Net Debt | -$123.4M | -$86.0M | -$96.6M | -$160.0M | -$403.4M | -$356.6M | -$385.2M | -$314.4M | -$276.5M | -$167.5M |
| Working Capital | $225.0M | $194.9M | $256.8M | $353.6M | $885.8M | $930.9M | $952.8M | $855.3M | $350.2M | $423.5M |
Financial Health
| Debt / Equity | 0.69 |
| Current Ratio | 2.89 |
Profitability
| Return on Equity | -44.00% |
| Return on Invested Capital | -26.15% |
| Return on Assets | -18.68% |
| Gross Margin | 76.13% |
| Operating Margin | -22.08% |
| Net Margin | -21.25% |
Related companies: AZTA · BLFS · ESTA · EVO · KMTS · NEOG · PLSE
Explore sector: Healthcare · Medical - Devices
More sections of NVCR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks